Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency chief counsel says exclusivity for better formulations may need to be considered.
You may also be interested in...
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
This time, the agency may be ready to agree with its advisory committee.